標的タンパク質分解誘導剤探索プラットフォーム RaPPIDS
Yusuke Tominari and Kanae Gamo, Medchem News, 34 (4), 211-215. (2024)
α-Parvin Expression in Breast Cancer Tissues: Correlation with Clinical Parameters and Prognostic Significance
Midori Takeda, Hiroaki Ito, Keisuke Kitahata, Sota Sato, Akira Nishide, Kanae Gamo, Shunsuke Managi, Tohru Tezuka, Akihiko Yoshizawa and Minsoo Kim, Cells 13(18), 1572 (2024).
The auxin-inducible degron 2 technology provides sharp degradation control in yeast, mammalian cells, and mice
Aisha Yesbolatova, Yuichiro Saito, Naomi Kitamoto, Hatsune Makino-Itou, Rieko Ajima, Risako Nakano, Hirofumi Nakaoka, Kosuke Fukui, Kanae Gamo, Yusuke Tominari, Haruki Takeuchi, Yumiko Saga, Ken-ichiro Hayashi and Masato T. Kanemaki, Nat Commun. 11, 5701 (2020).
An Efficient Approach Toward Drugging Undruggable Targets
Kanae Gamo, Naomi Kitamoto, Masato T. Kanemaki, and Yusuke Tominari (2020), Hilmar Weinmann and Craig Crews (eds.), Protein Degradation with New Chemical Modalities: Successful Strategies in Drug Discovery and Chemical Biology, London, The Royal Society of Chemistry, p167-183.
標的タンパク質分解誘導技術と創薬ベンチャーの動向
Yusuke Tominari and Kanae Gamo, Exp. Med. 38(14), 2020, p2342-2347.
DOI: https://www.yodosha.co.jp/jikkenigaku/book/9784758125352/index.html
蛋白質分解誘導剤の開発
Mitsutoshi Wayama, Kanae Gamo, and Yusuke Tominari, J. Mol. Targeted Ther. Cancer, 18(1), 2020, p56-62.
ファイメクス社の標的タンパク分解誘導技術
Yusuke Tominari, Farumasia, 56(3), 2020, p248-250.
Ligand-induced genetic degradation as a tool for target validation
Aisha Yesbolatova, Yusuke Tominari, and Masato T. Kanemaki. Drug Diecovery Today, Volume 31, April 2019, p91-98.